MX2019000749A - Formas cristalinas de 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il) -6-(2,2,6,6-tetrametiltetrahidro-2h-piran-4-il)piridin-3-il)-1h-i midazol-2-carboxamida. - Google Patents

Formas cristalinas de 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il) -6-(2,2,6,6-tetrametiltetrahidro-2h-piran-4-il)piridin-3-il)-1h-i midazol-2-carboxamida.

Info

Publication number
MX2019000749A
MX2019000749A MX2019000749A MX2019000749A MX2019000749A MX 2019000749 A MX2019000749 A MX 2019000749A MX 2019000749 A MX2019000749 A MX 2019000749A MX 2019000749 A MX2019000749 A MX 2019000749A MX 2019000749 A MX2019000749 A MX 2019000749A
Authority
MX
Mexico
Prior art keywords
dimethylcyclohex
pyran
imidazole
cyano
crystalline forms
Prior art date
Application number
MX2019000749A
Other languages
English (en)
Inventor
E Fawzy Nagy
Breslin David
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2019000749A publication Critical patent/MX2019000749A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Pyrane Compounds (AREA)

Abstract

La presente descripcion describe formas cristalinas de 4-ciano-N-[2-(4,4-dimetilciclohex-1-en-1-il)-6- 2,2,6,6-tetrametiltetrahidro-2H-piran-4-il)piridina-3-il]-1H-imid azol-2-carboxamida.
MX2019000749A 2016-07-18 2017-07-17 Formas cristalinas de 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il) -6-(2,2,6,6-tetrametiltetrahidro-2h-piran-4-il)piridin-3-il)-1h-i midazol-2-carboxamida. MX2019000749A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662363622P 2016-07-18 2016-07-18
PCT/US2017/042310 WO2018017444A1 (en) 2016-07-18 2017-07-17 Crystalline forms of 4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide

Publications (1)

Publication Number Publication Date
MX2019000749A true MX2019000749A (es) 2019-08-29

Family

ID=59631847

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019000749A MX2019000749A (es) 2016-07-18 2017-07-17 Formas cristalinas de 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il) -6-(2,2,6,6-tetrametiltetrahidro-2h-piran-4-il)piridin-3-il)-1h-i midazol-2-carboxamida.
MX2021006739A MX2021006739A (es) 2016-07-18 2019-01-17 Formas cristalinas de 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il) -6-(2,2,6,6-tetrametiltetrahidro-2h-piran-4-il)piridin-3-il)-1h-i midazol-2-carboxamida.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021006739A MX2021006739A (es) 2016-07-18 2019-01-17 Formas cristalinas de 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il) -6-(2,2,6,6-tetrametiltetrahidro-2h-piran-4-il)piridin-3-il)-1h-i midazol-2-carboxamida.

Country Status (16)

Country Link
US (1) US10314821B2 (es)
EP (1) EP3484872B1 (es)
JP (1) JP2019521159A (es)
KR (1) KR20190026910A (es)
CN (1) CN109952296A (es)
AR (1) AR109079A1 (es)
AU (1) AU2017299506B2 (es)
BR (1) BR112019000982A2 (es)
CA (1) CA3031230A1 (es)
EA (1) EA201990320A1 (es)
ES (1) ES2935647T3 (es)
MA (1) MA45685A (es)
MX (2) MX2019000749A (es)
TW (1) TWI752980B (es)
UY (1) UY37338A (es)
WO (1) WO2018017444A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
JP2011502266A (ja) * 2007-10-31 2011-01-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｆｍｓ治療に対する応答を評価するバイオマーカー
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
RS57103B1 (sr) * 2013-03-15 2018-06-29 Janssen Pharmaceutica Nv Supstituisani derivati piridina korisni kao inhibitori c-fms kinaze
US20160015700A1 (en) 2013-03-15 2016-01-21 Carla DE BOER 4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide for the treatment of hodgkin's lymphoma

Also Published As

Publication number Publication date
JP2019521159A (ja) 2019-07-25
CA3031230A1 (en) 2018-01-25
KR20190026910A (ko) 2019-03-13
AU2017299506A1 (en) 2019-02-07
EP3484872A1 (en) 2019-05-22
TW201808941A (zh) 2018-03-16
UY37338A (es) 2018-01-31
EA201990320A1 (ru) 2019-06-28
EP3484872B1 (en) 2022-11-30
AU2017299506B2 (en) 2021-08-05
US20180133197A1 (en) 2018-05-17
WO2018017444A1 (en) 2018-01-25
TWI752980B (zh) 2022-01-21
MA45685A (fr) 2019-05-22
AR109079A1 (es) 2018-10-24
US10314821B2 (en) 2019-06-11
ES2935647T3 (es) 2023-03-08
BR112019000982A2 (pt) 2019-05-14
MX2021006739A (es) 2021-07-15
CN109952296A (zh) 2019-06-28

Similar Documents

Publication Publication Date Title
PH12017550028A1 (en) Solid forms of an ask1 inhibitor
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
EP3376865A4 (en) 4 - ((6- (2,4-difluorophenyl) -1,1-difluoro-2-HYDROXY-3- (1 H
IL252089A0 (en) 2-amino-6-(difluoromethyl)-5,5,-difluoro-6-phenyl-6,5,4,3-tetrahydropyridines as BACE1 inhibitors
SI3227297T1 (sl) 4,6-substituirani-pirazolo(1,5-A)pirazini kot inhibitorji Janus kinaze
IL247319B (en) History of 2-hydroxy-6,4-diphenyl-[5,3,1]triazine as mpges-1 inhibitors
IL260908B (en) Substituted 2-(het)aryl-imidazolyl-carboxyamides as pest control agents
ZA201701131B (en) Novel 2,5-substituted pyrimidines as pde4 inhibitors
IL252844B (en) Process for preparing 4-(3-(-6-cyano-5-(trifluoromethyl)pyridin-3-yl)-4-oxo-2-thio-3,1-diazaspiro[5,4]-octan-1-yl) -2- fluoro-n-methylbenzamide
ZA201701132B (en) Novel 2,5-substituted pyrimidines as pde inhibitors
HUE051642T2 (hu) 8-amino-2-oxo-1,3-diaza-spiro-[4,5]-dekán származékok
HRP20181112T1 (hr) Supstituirani derivati azaspiro(4,5)dekana
EP3541801A4 (en) 4- (6- (2- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H
HRP20180940T1 (hr) Derivati supstituiranog azaspiro(4,5)dekana
EP3541797A4 (en) 4 - ((6- (2- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H
MX2021006739A (es) Formas cristalinas de 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il) -6-(2,2,6,6-tetrametiltetrahidro-2h-piran-4-il)piridin-3-il)-1h-i midazol-2-carboxamida.
HK1217918A1 (zh) 用於治療何杰金氏淋巴瘤的 -氰基- -二甲基環己- -烯- -基 -四甲基四氫- -吡喃- -基 吡啶- -基 -咪唑- -酰胺
HK1254355A1 (zh) Bace1抑制劑2-氨基-7a-苯基-3，4，4a，5，7，7a-六氫呋喃並[3，4-b]吡啶
TH1501006629A (th) อนุพันธ์พีร์โรโล[2,3-d]ไพริมิดีนในฐานะอะกอนิสต์ของ CB2 รีเซปเตอร์
UA93524U (uk) 5-(феноксиметил)-4-феніл-4н-1,2,4-триазол-3-тіол, що проявляє жарознижуючу активність
UA97068U (xx) 5-(феноксиметил)-4-етил-1,2,4-триазол-3-тіон, що виявляє гіпоглікемічну активність
UA106812U (uk) 3Н-ТІАЗОЛО[4,3-b]ХІНАЗОЛІН-1,9-ДІОН, ЩО ПРОЯВЛЯЄ АНТИЕКСУДАТИВНУ ДІЮ
JO3562B1 (ar) اشكال بلورية متعدة من القاعدة الحرة من 2-هيدروكسي-6-((2-(1-أيزوبروبيل-1h-بيرازول-5-يل)بيريدين-3-يل)ميثوكسي) بنزالديهيد
UA91310U (uk) [7-(4-МЕТОКСИФЕНІЛ)-5-(3,4-ДИМЕТОКСИФЕНІЛ)-2-ОКСО-3,5,6,7-ТЕТРАГІДРО-2Н-ТІОПІРАНО[2,3-d]ТІАЗОЛ-6-ІЛ]-ОКСОАЦЕТАТНА КИСЛОТА, ЩО ПРОЯВЛЯЄ АНТИЕКСУДАТИВНУ ДІЮ
UA93023U (uk) 2-(3-хлоротетрагідрофуран-2-іл)-4-тозил-5-(трифторометил)-2н-1,2,3-триазол